ClinicalTrials.gg
CompletedNCT05516134AAMUpdated Apr 29, 2025Results posted

All About Me: An Intervention to Ease the Transition to Long Term Care

An interventional study of SAFE at Home in Dementia, Alzheimer Disease and Dementia, Vascular, sponsored by Hopeful Aging. Completed at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Hopeful Aging · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.

Enrollment
553rd of 846
51 · median 93
Started
2024
with 77 others
No phase
562 of 1,051
118 open now
Registered
732nd of 1,051
by date

Among the 1,051 studies in Dementia with a site in United States, this one is the 553rd largest by enrollment of the 846 interventional ones that give a count, is one of 78 that started in 2024, is one of 562 with no phase, and was the 732nd registered.

Dementia

2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.

Browse Dementia studies →

Open to participants now

211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,051 studies in Dementia with a site in United States, or all of them as a file.
02

Study summary

This Phase I study will involve initial development and evaluation of an innovative cross-platform software app called All About Me (AAM), which will consist of Serious Digital Health Games (SDHGs) for PWD. The AAM app will assist staff in providing person-centered care and enable residents to improve relationships with one another and with staff, thereby promoting a sense of community. This Phase I study has three Specific Aims: (1) Develop an Alpha version of the AAM App, (2) Examine acceptability of and satisfaction with the AAM App, and (3) Examine the impact of the Resident Game Bundle / Survey Says Game on engagement/affect.

Read the detailed description

Study Design: The study will utilize a quasi-experimental pre-post design.

Sample:

PWD: Twenty-four PWD will take part in the study, including 12 ALF residents and 12 living in a NH.

Family Members: Twenty-four family members will also take part in the study-i.e., one for each PWD. In some cases, the "family member" may be a friend or legally authorized representative.

Staff Members: Twelve LTC staff members will take part in the quasi-experiment-five at the ALF and five at the NH.

Inclusion/Exclusion Criteria:

PWD must reside in an ALF or NH, be 60+ years old, speak and read English, be diagnosed with dementia (of any type), and score at least eight on the MMSE.

Family Members, LTC Staff Members, and Focus Group Staff Members must be 18+ years old and speak and read English.

Baseline Period/Measures:

PWD: During Month 8, the following data will be collected via chart review: demographics, medications, diagnoses (including type of dementia), and primary language. In addition, the MMSE48 and the Dementia Quality of Life Scale (DEMQOL)50 will be administered via direct interview. The Neuropsychiatric Inventory-Nursing Home (NPI-NH),51,52 done via staff interview, will be used to collect data on challenging behaviors. PWD will also be observed taking part in standard activities using the Menorah Park Engagement Scale (MPES).53 The MPES is an observational scale that measures four types of engagement: Constructive Engagement (motor/verbal behavior exhibited clearly in response to the target activity); Passive Engagement (listening/watching a target activity); Distracted Engagement (motor/verbal behavior exhibited in response to something other than the target activity); and Non-Engagement/Apathy (outward signs/indicators of apathy, such as sleeping, closing one's eyes, and staring into space). The MPES also measures Pleasure, defined as clearly observable smiling/laughing. MPES data for standard activities will allow us to conduct a robust comparison to the RGB/Survey Says Game.

Family Members: researchers will interview family members to obtain demographics.

LTC Staff Members: Researchers will only interview staff members to obtain demographics during Phase I. Since this study is about development and feasibility testing, we do not want to unnecessarily burden staff with measures in Phase I. In the future Phase II, we will use the Caregiving Difficulty Scale-Intellectual Disability (CDS-ID)54 and the Maslach Burnout Inventory (MBI).

Intervention Period/Measures: During Month 9, family members will play the FFAM Game with their loved one on an Android tablet. A relatively lengthy four-week time period was chosen to ensure that even very busy family members will find time to play the game. We expect the game to take 60 minutes to complete, but we will encourage family members to split up the game into two 30-minute sessions. The app will automatically capture data about how many questions/items were completed and the length of time to complete the game. In addition, after playing the FFAM Game, family members and PWD will be asked questions related to ease of use and satisfaction. During Month 10, PWD will play the RGB/Survey Says Game twice per week for four weeks. The game will be played on an Android tablet, which will be connected to a large screen TV. The activity will be facilitated by a researcher; however, each staff member will observe an RGB/Survey Says Game session at least once, so that they can provide feedback about the game. An RA (not the researcher facilitating game) will observe PWD with the MPES while they are taking part in the Survey Says Game. After each Survey Says Game session, PWD and Staff Members will be asked questions related to ease of use and satisfaction (e.g., did you find the game easy to use? Did you enjoy the game? Would you recommend it to others?) During this same time period, LTC staff members will use the MRM daily when working with PWD. Each staff member will be given an Android smartphone and they will be encouraged to briefly review information about PWD before interacting with and/or providing care to them. At the end of this time period, staff will be asked questions related to ease of use and satisfaction for the MRM (e.g., Did you find it easy to use? Would you recommend it to others? Did it help you provide better care?)

Treatment Fidelity/Process Measures: In the backend of the app, a variety of treatment fidelity/process measures will automatically be collected by the app, including dates/times each participant used the app, length of time for each session; number of buttons pressed in each activity, and dates/times of any crashes.

Post-Treatment/Distal Measures:

PWD: The DEMQOL and NPI-NH will be re-administered. Family Members: No post-treatment measures will be taken. LTC Staff Members: No post-treatment measures will be taken.

Please note that, since the purpose of Phase I is to demonstrate proof of concept and feasibility, and since the intervention period will be relatively brief, changes are not expected from baseline to post-treatment on longer-term measures (i.e., the DEMQOL and NPI-NH). These measures are being used in Phase I exclusively to obtain means and standard deviations to conduct a power analysis to ensure that a sufficiently sized sample is used in Phase II.

Analyses: The AAM App will be considered successful if the following results are found: (1) at least 85% of participants complete 85% of the FFAM Game; (2) mean completion time for the FFAM Game is 45-75 minutes; (3) at least 85% of family members and PWD are satisfied with the FFAM Game and find it easy to use; (4) for PWD, levels of positive engagement/affect are higher, and levels of negative engagement are lower, during the Survey Says Game, as compared to standard programming (based upon a paired sample t-test); with the proposed sample size, and using means and standard deviations from the previous studies by the PI, we will have a power of 93% to detect effects (alpha = .05; one-tailed test). (5) at least 85% of PWD and LTC staff members are satisfied with the Survey Says Game and find it easy to use; and (6) at least 85% of LTC staff members are satisfied with the My Resident Module and find it easy to use.

03

Conditions studied

  • Dementia
  • Alzheimer Disease
  • Dementia, Vascular
  • Dementia, Mixed
  • Dementia of Alzheimer Type
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must be 60+ years old
  • must speak and read English
  • must have a clinical diagnosis of dementia (of any type)
  • must score at least eight on the Mini-Mental Status Examination ()

Exclusion criteria

Exclusion Criteria:

-shows signs of rapid physical / cognitive decline over the past six months, as indicated by medical records

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Treatment

    Participants who receive the intervention (all)

    Behavioral: SAFE at Home

Interventions

  • BehavioralSAFE at Home

    The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale

    Constructive Engagement on the Menorah Park Engagement Scale is defined as doing or commenting on something related to the target activity. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Constructive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome.

    Time frame: Baseline (Weeks 1-4) and Treatment (Weeks 5-10)

  2. Change From Baseline to Treatment for Passive Engagement on the Menorah Park Engagement Scale

    Passive Engagement on the Menorah Park Engagement Scale is defined as listening or watching something related to the target activity. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Passive Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

    Time frame: Baseline (Weeks 1-4) and Treatment (Weeks 5-10)

  3. Change From Baseline to Treatment for Other Engagement on the Menorah Park Engagement Scale

    Other Engagement on the Menorah Park Engagement Scale is defined as doing, commenting, listening, or watching something NOT related to the target activity. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Other Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

    Time frame: Baseline (Weeks 1-4) and Treatment (Weeks 5-10)

  4. Change From Baseline to Treatment for Non-Engagement on the Menorah Park Engagement Scale

    Non-Engagement on the Menorah Park Engagement Scale is defined as sleeping and/or staring into space. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Non-Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

    Time frame: Baseline (Weeks 1-4) and Treatment (Weeks 5-10)

  5. Change From Baseline to Treatment for Pleasure on the Menorah Park Engagement Scale

    Pleasure on the Menorah Park Engagement Scale is defined as clearly observable laughing or smiling. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Pleasure is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

    Time frame: Baseline (Weeks 1-4) and Treatment (Weeks 5-10)

Secondary outcomes

  1. Change From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)

    The Dementia Related Quality of Life Scale is a 28 item scale that examines quality of life in persons with dementia. The score ranges for 28 to 112. Higher scores represent a better outcome.

    Time frame: Baseline (Weeks 1-4) and Post-Treatment (Week 11)

  2. Change From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)

    The NPI-NH examines 10 types of neuropsychiatric symptoms in persons with dementia, with the FxS score looking creating a composite score that takes into account frequency and severity of the symtoms. The score ranges from 0 to 120. Lower scores represent a better outcome.

    Time frame: Baseline (Weeks 1-4) and Post-Treatment (Week 11)

  3. Change From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)

    The 15-item Geriatric Depression Scale (GDS-SF) is a screening tool used to assess depressive symptoms in older adults. Each item is answered with a "Yes" or "No"\*\* response, with a total score ranging from 0 to 15, where higher scores indicate greater depressive symptoms. A score of 5 or more\*\* suggests possible depression, warranting further clinical evaluation.

    Time frame: Baseline (Weeks 1-4) and Post-Treatment (Week 11)

  4. Satisfaction With the App

    Satisfaction with the app

    Time frame: Treatment (Weeks 5-11)

07

Results

Posted Apr 29, 2025

Participant flow

Participant flow — Overall Study
MilestoneTreatmentFamily MembersStaff Members
Started26916
Completed25916
Not completed100
Withdrew: Lost to follow-up100

Outcome measures

PrimaryChange From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale

Constructive Engagement on the Menorah Park Engagement Scale is defined as doing or commenting on something related to the target activity. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Constructive Engagement is zero (0) and the maximum score is two (2). Higher scores represent a better outcome.

Time frame:
Baseline (Weeks 1-4) and Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale
score on a scaleTreatment
Change From Baseline to Treatment for Constructive Engagement on the Menorah Park Engagement Scale0.83 ± 0.45
Statistical analysis
  • Treatment · t-test, 2 sided · p = <0.01
PrimaryChange From Baseline to Treatment for Passive Engagement on the Menorah Park Engagement Scale

Passive Engagement on the Menorah Park Engagement Scale is defined as listening or watching something related to the target activity. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Passive Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

Time frame:
Baseline (Weeks 1-4) and Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Passive Engagement on the Menorah Park Engagement Scale
score on a scaleTreatment
Change From Baseline to Treatment for Passive Engagement on the Menorah Park Engagement Scale1.2 ± 0.86
Statistical analysis
  • Treatment · t-test, 2 sided · p = <.01
PrimaryChange From Baseline to Treatment for Other Engagement on the Menorah Park Engagement Scale

Other Engagement on the Menorah Park Engagement Scale is defined as doing, commenting, listening, or watching something NOT related to the target activity. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Other Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

Time frame:
Baseline (Weeks 1-4) and Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Other Engagement on the Menorah Park Engagement Scale
score on a scaleTreatment
Change From Baseline to Treatment for Other Engagement on the Menorah Park Engagement Scale-1.24 ± 0.78
Statistical analysis
  • Treatment · t-test, 2 sided · p = <.01
PrimaryChange From Baseline to Treatment for Non-Engagement on the Menorah Park Engagement Scale

Non-Engagement on the Menorah Park Engagement Scale is defined as sleeping and/or staring into space. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Non-Engagement is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

Time frame:
Baseline (Weeks 1-4) and Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Non-Engagement on the Menorah Park Engagement Scale
score on a scaleTreatment
Change From Baseline to Treatment for Non-Engagement on the Menorah Park Engagement Scale-.17 ± 0.34
Statistical analysis
  • Treatment · t-test, 2 sided · p = .03
PrimaryChange From Baseline to Treatment for Pleasure on the Menorah Park Engagement Scale

Pleasure on the Menorah Park Engagement Scale is defined as clearly observable laughing or smiling. During baseline, multiple observations of "standard" activities were observed and a mean was calculated. Then, again, during treatment, multiple activities were observed and a mean was calculated. The minimum value for Pleasure is zero (0) and the maximum score is two (2). Lower scores represent a better outcome.

Time frame:
Baseline (Weeks 1-4) and Treatment (Weeks 5-10)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment for Pleasure on the Menorah Park Engagement Scale
score on a scaleTreatment
Change From Baseline to Treatment for Pleasure on the Menorah Park Engagement Scale.31 ± .35
Statistical analysis
  • Treatment · t-test, 2 sided · p = <.01
SecondaryChange From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)

The Dementia Related Quality of Life Scale is a 28 item scale that examines quality of life in persons with dementia. The score ranges for 28 to 112. Higher scores represent a better outcome.

Time frame:
Baseline (Weeks 1-4) and Post-Treatment (Week 11)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)
score on a scaleTreatment
Change From Baseline to Treatment on Dementia Related Quality of Life (DEMQOL)2.40 ± 7.16
Statistical analysis
  • Treatment · t-test, 2 sided · p = .11
SecondaryChange From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)

The NPI-NH examines 10 types of neuropsychiatric symptoms in persons with dementia, with the FxS score looking creating a composite score that takes into account frequency and severity of the symtoms. The score ranges from 0 to 120. Lower scores represent a better outcome.

Time frame:
Baseline (Weeks 1-4) and Post-Treatment (Week 11)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)
score on a scaleTreatment
Change From Baseline to Treatment on the Neuropsychiatric Inventory-Nursing Home (NPI-NH), Frequency x Severity Score (FxS)-9.1 ± 12.2
Statistical analysis
  • Treatment · t-test, 2 sided · p = <.01
SecondaryChange From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)

The 15-item Geriatric Depression Scale (GDS-SF) is a screening tool used to assess depressive symptoms in older adults. Each item is answered with a "Yes" or "No"\*\* response, with a total score ranging from 0 to 15, where higher scores indicate greater depressive symptoms. A score of 5 or more\*\* suggests possible depression, warranting further clinical evaluation.

Time frame:
Baseline (Weeks 1-4) and Post-Treatment (Week 11)
Reported as:
Mean · score on a scale
Change From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)
score on a scaleTreatment
Change From Baseline to Treatment on the Geriatric Depression Scale-Short Form (GDS-SF)-0.97 ± 2.8
Statistical analysis
  • Treatment · t-test, 2 sided · p = 0.09
SecondarySatisfaction With the App

Satisfaction with the app

Time frame:
Treatment (Weeks 5-11)
Reported as:
Number · % who said they were satisfied (yes/no)
Satisfaction With the App
% who said they were satisfied (yes/no)TreatmentFamily MembersStaff Members
Satisfaction With the App96100100

Adverse events

Collected over 11 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment0/26 (0%)0/26 (0%)0/26 (0%)
Family Members0/9 (0%)0/9 (0%)0/9 (0%)
Staff Members0/16 (0%)0/16 (0%)0/16 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Persons With Dementia Who Recieved the InterventionFamily Members Who Participated in the Intervention With Their Loved OneStaff MembersTotal
Mean82.8 ± 10.268.9 ± 13.441.6 ± 14.168.5 ± 21.4
Sex: Female, Male
Sex: Female, Male(Participants)Persons With Dementia Who Recieved the InterventionFamily Members Who Participated in the Intervention With Their Loved OneStaff MembersTotal
Female1261432
Male143219
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Persons With Dementia Who Recieved the InterventionFamily Members Who Participated in the Intervention With Their Loved OneStaff MembersTotal
Hispanic or Latino0011
Not Hispanic or Latino2691550
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Persons With Dementia Who Recieved the InterventionFamily Members Who Participated in the Intervention With Their Loved OneStaff MembersTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American90817
White159832
More than one race1001
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Persons With Dementia Who Recieved the InterventionFamily Members Who Participated in the Intervention With Their Loved OneStaff MembersTotal
United States2691651
08

Study locations

1 site
  • Hopeful Aging
    Winchester, Massachusetts 01890, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jul 2024, 2 months.

Results were first posted in Apr 2025, 9 months after primary completion.

Of 46 industry-sponsored interventional studies with no phase under Dementia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 2 months is below that.

Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 25, 2022
StartActual
Apr 18, 2024
Primary completionActual
Jul 5, 2024
CompletionActual
Jul 5, 2024
Results first posted
Apr 29, 2025
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05516134
Lead sponsor
Hopeful Aging
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Apr 18, 2024
Primary completion
Jul 5, 2024
Completion
Jul 5, 2024
Results posted
Apr 29, 2025
Last update
Apr 29, 2025

Study contacts

Michael Skrajner, MA
principal investigator · Hopeful Aging

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion